The estimated Net Worth of Bros. Advisors Lp667, L.P.B... is at least $9.89 Bilhão dollars as of 30 November 2021. Bros B owns over 394,895 units of Seagen Inc stock worth over $9,828,965,765 and over the last 3 years Bros sold SGEN stock worth over $63,396,443.
Bros has made over 1 trades of the Seagen Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Bros sold 394,895 units of SGEN stock worth $63,396,443 on 30 November 2021.
The largest trade Bros's ever made was selling 394,895 units of Seagen Inc stock on 30 November 2021 worth over $63,396,443. On average, Bros trades about 394,895 units every 0 days since 2021. As of 30 November 2021 Bros still owns at least 42,947,504 units of Seagen Inc stock.
You can see the complete history of Bros B stock trades at the bottom of the page.
Over the last 22 years, insiders at Seagen Inc have traded over $729,924,224 worth of Seagen Inc stock and bought 35,347,908 units worth $1,433,871,526 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Felixbaker Julian Baker Bro..., eBrothers Life Sciences Capi.... On average, Seagen Inc executives and independent directors trade stock every 8 days with the average trade being worth of $18,157,295. The most recent stock trade was executed by David R Epstein on 10 November 2023, trading 10,620 units of SGEN stock currently worth $2,262,166.
seattle genetics, co-founded by clay siegall, is a biotechnology company leading the field of antibody-drug conjugates (adcs) for the treatment of cancer. our technology is designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. our lead program, adcetris® (brentuximab vedotin), is the first in a new class of adcs and, in collaboration with takeda pharmaceutical company limited, is approved in more than 55 countries. to expand on the adcetris opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in a range of other lymphoma and non-lymphoma settings. seattle genetics is also advancing a robust pipeline of clinical-stage programs, including sgn-cd19a, sgn-cd33a, sgn-liv1a, sgn-cd70a, asg-22me, asg-15me and sea-cd40. seattle genetics has collaborations for its adc technology with a number of leading biotechnology and pharmaceutical companies, including abbvie, agensys
Seagen Inc executives and other stock owners filed with the SEC include: